We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.
- Authors
Lee, Hae Young; Ko, Seung-Hyun; Park, Sungjoon; Kim, Kyuho; Kim, Song-Yi; Cho, In-Jeong; Cho, Eun Joo; Kim, Hyeon Chang; Park, Jae-Hyeong; Ryu, Sung Kee; Moon, Min Kyong; Ihm, Sang-Hyun; Korean Society of Hypertension
- Abstract
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension. However, the current non-pharmacological therapies have limitations for achieving or maintaining ideal body weight. Recently, glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated excellent weight control effects, accompanied by corresponding reductions in blood pressure. GLP1-RAs have shown cardiovascular and renal protective effects in cardiovascular outcome trials both in primary and secondary prevention. In this document, the Korean Society of Hypertension intends to remark the current clinical results of GLP1-RAs and recommend the government and health-policy makers to define obesity as a disease and to establish forward-looking policies for GLP1-RA treatment for obesity treatment, including active reimbursement policies.
- Publication
Clinical hypertension, 2024, Vol 30, Issue 1, p24
- ISSN
2056-5909
- Publication type
Journal Article
- DOI
10.1186/s40885-024-00279-4